Diamyd Medical ended 2025 on a positive note. After discussions with the FDA, the company has accelerated the schedule for its phase III study DIAGNODE 3 by bringing forward the primary efficacy reading from 24 to 15 months. In an interview with BioStock, CEO Ulf Hannelius and board member Dr. Karin Rosén talk about what the adjusted timeline may mean going forward, what to expect from the preliminary readout in March 2026 and how the Nobel Prize in Medicine 2025 can be linked to Diamyd Medical's work.
See the interview with Diamyd Medical's CEO Ulf Hannelius and board member Dr. Karin Rosén, in English, below.
The content of BioStock's news and analysis is independent, but BioStock's operations are to some extent financed by companies in the industry. This post refers to a company from which BioStock has received funding.